Cargando…

Ticagrelor: The First Reversibly Binding Oral P2Y(12) Receptor Antagonist

Ticagrelor (AZD6140) is the first reversibly binding oral P2Y(12) receptor antagonist that blocks ADP-induced platelet aggregation. Unlike thienopyridines, which irreversibly bind to the P2Y(12) receptor for the lifetime of the platelet, ticagrelor binds reversibly to the receptor and exhibits rapid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Husted, Steen, van Giezen, JJJ
Formato:	Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2009
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948430/ https://www.ncbi.nlm.nih.gov/pubmed/19604248 http://dx.doi.org/10.1111/j.1755-5922.2009.00096.x

Ejemplares similares

Ticagrelor: The first approved reversible oral antiplatelet agent
por: Goel, Divya
Publicado: (2013)

Oral Delivery of the P2Y(12) Receptor Antagonist Ticagrelor Prevents Loss of Photoreceptors in an ABCA4(−/−) Mouse Model of Retinal Degeneration
por: Lu, Wennan, et al.
Publicado: (2019)

The reversible P2Y(12) antagonist ACT‐246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat
por: Rey, Markus, et al.
Publicado: (2017)

P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets
por: Gasecka, Aleksandra, et al.
Publicado: (2020)

Case Study: Ticagrelor in PLATO and Prasugrel in TRITON-TIMI 38 and TRILOGY-ACS Trials in Patients With Acute Coronary Syndromes
por: Husted, Steen, et al.
Publicado: (2016)

The P2Y(12) Receptor Antagonist Ticagrelor Reduces Lysosomal pH and Autofluorescence in Retinal Pigmented Epithelial Cells From the ABCA4(-/-) Mouse Model of Retinal Degeneration
por: Lu, Wennan, et al.
Publicado: (2018)

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y(12) receptor between selatogrel and oral P2Y(12) antagonists
por: Henrich, Andrea, et al.
Publicado: (2021)

To Pretreat or Not to Pretreat (With Oral P2Y12 Antagonists)? That is the Question
por: Lowenstern, Angela, et al.
Publicado: (2017)

Antiplatelet effects of aspirin vary with level of P2Y(12) receptor blockade supplied by either ticagrelor or prasugrel
por: KIRKBY, N S, et al.
Publicado: (2011)

Ticagrelor: An emerging oral antiplatelet agent
por: Juneja, Shivani, et al.
Publicado: (2013)

The TICONC (Ticagrelor-Oncology) Study: Implications of P2Y(12) Inhibition for Metastasis and Cancer-Associated Thrombosis
por: Wright, Joy R., et al.
Publicado: (2020)

Mind the Gap: Model-Based Switching from Selatogrel to Maintenance Therapy with Oral P2Y12 Receptor Antagonists
por: Hsin, Chih-hsuan, et al.
Publicado: (2023)

Impact of opioids on P2Y(12) receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial
por: Tavenier, Anne H, et al.
Publicado: (2020)

Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study
por: Storey, Robert F., et al.
Publicado: (2014)

Identification of a New Morpholine Scaffold as a P2Y12 Receptor Antagonist
por: Ahn, Young Ha, et al.
Publicado: (2016)

The P2Y12 Receptor Antagonist Selatogrel Dissolves Preformed Platelet Thrombi In Vivo
por: Crescence, Lydie, et al.
Publicado: (2021)

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel
por: Schilling, Uta, et al.
Publicado: (2022)

P2Y(12) Receptor Antagonist Clopidogrel Attenuates Lung Inflammation Triggered by Silica Particles
por: Santana, Patricia Teixeira, et al.
Publicado: (2020)

P2Y12 Inhibitor Monotherapy with Clopidogrel versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
por: Chen, Po-Wei, et al.
Publicado: (2020)

Antiplatelet Drug Ticagrelor Enhances Chemotherapeutic Efficacy by Targeting the Novel P2Y12-AKT Pathway in Pancreatic Cancer Cells
por: Elaskalani, Omar, et al.
Publicado: (2020)

Adenosine Receptor Agonists Exhibit Anti-Platelet Effects and the Potential to Overcome Resistance to P2Y(12) Receptor Antagonists
por: Wolska, Nina, et al.
Publicado: (2019)

P2Y12 Receptor Antagonist, Clopidogrel, Does Not Contribute to Risk of Osteoporotic Fractures in Stroke Patients
por: Jørgensen, Niklas R., et al.
Publicado: (2017)

Platelet Reactivity And Circulating Platelet-Derived Microvesicles Are Differently Affected By P2Y(12) Receptor Antagonists
por: Chyrchel, Bernadeta, et al.
Publicado: (2019)

Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial
por: James, Stefan, et al.
Publicado: (2010)

Comparison of the effects of the GPIIb-IIIa antagonist Zalunfiban and the P2Y12 antagonist Selatogrel on Platelet Aggregation
por: Curry, Benjamin J., et al.
Publicado: (2023)

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
por: Mujer, Mark Terence P., et al.
Publicado: (2020)

Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial
por: Lindholm, Daniel, et al.
Publicado: (2014)

Salvianolic acids from antithrombotic Traditional Chinese Medicine Danshen are antagonists of human P2Y(1) and P2Y(12) receptors
por: Liu, Xuyang, et al.
Publicado: (2018)

Comparative In Vitro Study of Various α(2)-Adrenoreceptor Agonist Drugs for Ticagrelor Reversal
por: Porta Bonete, Guillaume, et al.
Publicado: (2020)

Development of selective agonists and antagonists of P2Y receptors
por: Jacobson, Kenneth A., et al.
Publicado: (2008)

When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y(12) Inhibition Induced by Ticagrelor
por: Capodanno, Davide, et al.
Publicado: (2020)

Unraveling the pharmacokinetic interaction of ticagrelor and MEDI2452 (Ticagrelor antidote) by mathematical modeling
por: Almquist, J, et al.
Publicado: (2016)

The Use Pattern and Clinical Impact of Novel P2Y12 Receptor Antagonists for Acute Myocardial Infarction in Korea
por: Kim, Soo-Joong
Publicado: (2017)

GLS-409, an Antagonist of Both P2Y(1) and P2Y(12), Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation
por: Smolensky Koganov, Elena, et al.
Publicado: (2018)

Membrane Environment Modulates Ligand-Binding Propensity of P2Y12 Receptor
por: Haghighi, Fatemeh, et al.
Publicado: (2021)

Stabilizing Role of Platelet P2Y(12) Receptors in Shear-Dependent Thrombus Formation on Ruptured Plaques
por: Nergiz-Unal, Reyhan, et al.
Publicado: (2010)

A randomised, investigator-initiated, clinical trial of the effects of fentanyl on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: rationale and design of the Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial
por: Tavenier, A. H., et al.
Publicado: (2019)

Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal
por: Brown, Karen S., et al.
Publicado: (2016)

Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
por: Andell, Pontus, et al.
Publicado: (2015)

The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial
por: Husted, Steen, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4ko1ssvhf1t5b41non10g3uojn